PTEN‐PI3K pathway alterations in advanced prostate cancer and clinical implications

Background Despite significant advances in molecular characterization and therapeutic targeting of advanced prostate cancer, it remains the second most common cause of cancer death in men in the United States. The PI3K (Phosphatidylinositol 3‐kinase)/AKT (AKT serine/threonine kinase)/mTOR (mammalian...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	The Prostate Ročník 82; číslo S1; s. S60 - S72
Hlavný autor:	Choudhury, Atish D.
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States Wiley Subscription Services, Inc 01.08.2022
Predmet:	1-Phosphatidylinositol 3-kinase AKT AKT protein Biomarkers capivasertib Cell migration Cell proliferation Cell survival Clinical trials Humans Immune checkpoint inhibitors ipatasertib Kinases LY3023414 Male mTOR Phosphatidylinositol 3-Kinases - metabolism PI3K PIK3CA Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use Prostate cancer Prostatic Neoplasms - drug therapy Protein-serine/threonine kinase Proto-Oncogene Proteins c-akt - metabolism PTEN PTEN Phosphohydrolase - metabolism PTEN protein Rapamycin Ribose samotolisib Signal Transduction Tensin Therapeutic targets TOR protein TOR Serine-Threonine Kinases - metabolism Tumor suppressor genes Tumors prostate cancer samotolisib LY3023414 PI3K PIK3CA ipatasertib PTEN mTOR capivasertib AKT
ISSN:	0270-4137, 1097-0045, 1097-0045
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!